Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Merle Foster who wrote (258)	12/18/1998 1:30:00 PM
From: Thomas Kirwin	Respond to of 422

Earnings Guesstimate Sid, My earnings guesstimate is posted under the "Earnings" heading for Immucor on this thread located at... techstocks.com The $4 million dollar purchase commitment press release is tremendous. Immucor will book $1.6 million dollars in sales this quarter. Let me see.... ummmmmm even at a conservative 30% profit margin the result could be $0.06 per share less income tax at 47% leaves Immucor with approximately $0.03 more eps +/- $0.01. Add the $.03 to the $.08 eps reported last quarter. Ummmmmmm that equals $0.11 which is a 83% increase over the $0.06 eps reported for the same quarter last year. WOW! That should get us noticed. Of course my calculations may contain a margin of error +/- $0.01 which gives us an eps guesstimate range of $0.10 to $0.12 for the second quarter. Lets look at the meat of the press release again shall we... ''We are very pleased with the performance of our capital sales force in the quarter following the United States Food and Drug Administrations clearance to market the ABS2000. In-house orders for the entire instrument family will be $4.0 million which is a dramatic increase compared to previously disclosed projections of $1.6 million. Some early purchase orders require an evaluation before customer acceptance. The Company expects all placements to be accepted, but has elected to defer revenue recognition until the third quarter. Booked second quarter sales will be $1.6 million and will result in a $2.4 million dollar third quarter sales backlog.'' Remember that Immucor's instrument family has contributed negligible revenues to date in past quarters. The demand is there and FDA approval has given Immucor more credibility and visibility among current and potential customers. I for one can live with $1.6 million in booked sales with much more to follow! Don't forget the reagent trail and corresponding revenues as I suspect that most of these sales are to new customers of Immucor. Go Immucor! Tom